Predictive Oncology Adjourns Special Meeting of Stockholders
August 11 2021 - 8:30AM
Predictive Oncology
(Nasdaq: POAI), a
knowledge-driven company focused on applying artificial
intelligence (“AI”) to personalized medicine and drug discovery,
announced today that the Company’s Special Meeting of Stockholders,
which was convened at 3:00 p.m. Central Time on August 10, 2021,
has been adjourned for the purpose of soliciting more votes on the
proposal to approve an amendment to the Company’s certificate of
incorporation to increase the number of authorized shares of
Company common stock from 100,000,000 to 200,000,000 (the “Charter
Proposal”). The Special Meeting has been scheduled to reconvene on
August 17, 2021 at 3:00 p.m. Central time at the offices of Maslon
LLP, 3300 Wells Fargo Center, 90 South Seventh Street, Minneapolis,
MN 55402.
The other proposals that were voted on at the
Special Meeting were all approved by the requisite votes of the
stockholders, including (i) an amendment to the Amended and
Restated 2012 Stock Incentive Plan to increase the reserve of
shares of common stock authorized for issuance thereunder by
1,500,000, to 3,250,000; (ii) the issuance of additional shares of
common stock of the Company pursuant to a previously approved
equity line of credit arrangement; (iii) ratification of the
appointment of Baker Tilly US, LLP as the Company’s independent
registered public accounting firm for the fiscal year ending
December 31, 2021; and (iv) a proposal to adjourn the Special
Meeting, if necessary, to solicit additional proxies for approval
of the Charter Proposal or any of the other proposals as
applicable, in the event that there are not sufficient votes at the
time of the Special Meeting to approve any such proposal.
During the period of the adjournment, the
Company will continue to solicit proxies from its stockholders with
respect to the Charter Proposal. Proxies previously submitted in
respect to the Special Meeting with respect to the Charter Proposal
will be voted at the reconvened meeting unless properly
revoked.
Correction: The Charter
Proposal (Proposal #1 at the Special Meeting) is considered
“routine” under rules of the New York Stock Exchange, contrary to a
statement in the proxy statement dated July 7, 2021 with respect to
the Special Meeting. Therefore, if the beneficial owner of shares
held in street name does not provide voting instructions, the
broker or nominee can still vote the shares with respect to the
Charter Proposal.
The Company encourages all stockholders who have
not yet voted to do so as soon as possible. For additional
information please refer to the proxy statement dated July 7, 2021
available at www.sec.gov and Predictive’s investor relations web
site at http://www.proxypush.com/poai. If you have any questions,
or need assistance in voting, please contact our proxy solicitor
Regan & Associates, Inc., at (212) 587-3005 or
800-737-3426.
About Predictive Oncology
Inc. Predictive Oncology (NASDAQ: POAI) operates
through three segments (Skyline, Helomics and Soluble Biotech),
which contain four subsidiaries: Helomics, TumorGenesis, Skyline
Medical and Soluble Biotech.
Helomics applies artificial intelligence to its
rich data gathered from patient tumors to both personalize cancer
therapies for patients and drive the development of new targeted
therapies in collaborations with pharmaceutical companies.
TumorGenesis Inc. specializes in media that help cancer cells grow
and retain their DNA/RNA and proteomic signatures, providing
researchers with a tool to expand and study cancer cell types found
in tumors of the blood and organ systems of all mammals, including
humans. Skyline Medical markets its patented and FDA cleared
STREAMWAY System, which automates the collection, measurement and
disposal of waste fluid, including blood, irrigation fluid and
others, within a medical facility, through both domestic and
international divisions. Soluble Biotech is a provider of soluble
and stable formulations for proteins including vaccines,
antibodies, large and small proteins and protein complexes.
Forward-Looking
Statements: Certain matters discussed in this
release contain forward-looking statements. These forward-looking
statements reflect our current expectations and projections about
future events and are subject to substantial risks, uncertainties
and assumptions about our operations and the investments we make.
All statements, other than statements of historical facts, included
in this press release regarding our strategy, future operations,
future financial position, future revenue and financial
performance, projected costs, prospects, plans and objectives of
management are forward-looking statements. The words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,”
“target” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Our actual future
performance may materially differ from that contemplated by the
forward-looking statements as a result of a variety of factors
including, among other things, factors discussed under the heading
“Risk Factors” in our filings with the SEC. Except as expressly
required by law, the Company disclaims any intent or obligation to
update these forward-looking statements.
Investor Relations Contact:
Landon Capital Keith Pinder (404)
995-6671kpinder@landoncapital.net
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024